Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer.
Ana PissarraMariana MalheiroLeonor Vasconcelos de MatosAna Neto PlácidoPublished in: BMJ case reports (2019)
Colorectal cancer is the third most common cancer in men and the second in women. The standard chemotherapy regiment in stage III colon cancer is based in oxaliplatin. The most common side effects include neutropenia, peripheral neuropathy, vomiting and diarrhoea. Rhabdomyolysis due to oxaliplatin is rare, and there are no established guidelines for managing this adverse event. This report describes a case of a 52-year-old man, with a resected stage III colon cancer that started postoperative adjuvant chemotherapy with capecitabine plus oxaliplatin. After the second cycle, the patient developed distal muscle pain and weakness, with a total inability to walk. Blood tests showed an elevated creatine kinase and renal injury. Severe drug-related rhabdomyolysis was diagnosed. The goal of this case report is to discuss the side effect of adjuvant chemotherapy, given its rarity and severity.
Keyphrases
- acute kidney injury
- case report
- chemotherapy induced
- drug induced
- early onset
- chronic pain
- papillary thyroid
- early stage
- patients undergoing
- skeletal muscle
- clinical trial
- pain management
- minimally invasive
- clinical practice
- randomized controlled trial
- metabolic syndrome
- adipose tissue
- squamous cell carcinoma
- spinal cord injury
- type diabetes
- pregnant women
- spinal cord
- open label
- electronic health record
- study protocol
- postoperative pain